Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 2:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Erythropoietin (EPO) Clear all
Recruiting Phase 2 Interventional

Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants

NCT05340465
View directory record Official record
Conditions
Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Interventions
Darbepoetin Alfa, Low Molecular Weight Iron Dextran, Ferumoxytol injection, Oral iron supplements
Drug
Lead sponsor
University of Washington
Other
Eligibility
Up to 3 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Darbe Administration in Newborns Undergoing Cooling for Encephalopathy

NCT01471015
View directory record Official record
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 24 Hours
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Albuquerque, New Mexico • Nashville, Tennessee • Ogden, Utah + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

NCT00003138
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes
Interventions
Erythropoietin, Filgrastim, Transfusion
Biological · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
28
States / cities
Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

The Darbepoetin Alfa for Ischemic Surgical Complications (DISC) Dose Finding Trial

NCT00647998
View directory record Official record
Conditions
Spinal Ischemia, Stroke, Neuroprotection
Interventions
Darbepoetin alfa, Standard care
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

NCT01587898
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Azusa, California • Bakersfield, California • Chino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 4 Interventional

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

NCT00425126
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Epoetin Alfa
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 4 Interventional Results available

Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients

NCT01395823
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ergocalciferol supplementation, placebo
Dietary Supplement · Other
Lead sponsor
Dialysis Clinic, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Redding, California • Albany, Georgia • Shreveport, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants

NCT01235923
View directory record Official record
Conditions
Preterm Infants
Interventions
three times weekly Epo, weekly Epo
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
7 Days to 100 Days
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01906489
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 82 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
47
States / cities
Glendale, Arizona • Tucson, Arizona • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 5, 2026, 2:16 PM EDT
Recruiting Phase 2 Interventional

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
341
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 262 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

NCT00338286
View directory record Official record
Conditions
Breast Cancer, Neoplasm Metastasis
Interventions
Standard supportive care (packed RBC transfusion), epoetin alfa + packed RBC transfusion
Other · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
2,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
14
States / cities
Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Not applicable Interventional

The Safety and Effectiveness of r-HuEPO in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Are Anemic

NCT00002303
View directory record Official record
Conditions
HIV Infections, Cytopenias
Interventions
Epoetin alfa
Drug
Lead sponsor
Ortho Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Raritan, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

NCT00077623
View directory record Official record
Conditions
Anemia
Interventions
epoetin alfa or beta, methoxy polyethylene glycol-epoetin beta (Mircera)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
17
States / cities
Hot Springs, Arkansas • Los Angeles, California • Riverside, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 5, 2026, 2:16 PM EDT
Terminated Phase 2 Interventional Results available

A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

NCT00386152
View directory record Official record
Conditions
Neoplasms, Anemia, Cancer
Interventions
epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
76
States / cities
Glendale, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 2 Interventional

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

NCT02064426
View directory record Official record
Conditions
Anemia, Renal Insufficiency, Chronic
Interventions
Molidustat (BAY85-3934), Epoetin alfa/beta
Drug · Biological
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
Azusa, California • Long Beach, California • Lynwood, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Oct 5, 2026, 2:16 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Erythropoietin Effects After Traumatic Brain Injury

NCT00260052
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Erythropoietin administration
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 5, 2026, 2:16 PM EDT
Terminated Phase 4 Interventional Results available

Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin

NCT03277183
View directory record Official record
Conditions
Anemia, CKD, Atherosclerosis, Cardiovascular
Interventions
Low dose erythropoietin, High dose erythropoietin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

NCT02648347
View directory record Official record
Conditions
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
208
States / cities
Huntsville, Alabama • Tuscumbia, Alabama • Glendale, Arizona + 148 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2022 · Synced Oct 5, 2026, 2:16 PM EDT
Terminated Phase 3 Interventional Results available

Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease

NCT00436748
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease, Kidney Disease
Interventions
Darbepoetin Alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Year to 18 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 2 Interventional

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

NCT00053001
View directory record Official record
Conditions
Anemia, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
epoetin alfa, thalidomide
Biological · Drug
Lead sponsor
Fallon Clinic
Industry
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
2
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 5, 2026, 2:16 PM EDT
Terminated Phase 4 Interventional

Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial

NCT00476619
View directory record Official record
Conditions
Contrast Induced Nephropathy
Interventions
erythropoeitin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide

NCT00283621
View directory record Official record
Conditions
Sarcoma
Interventions
Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 5, 2026, 2:16 PM EDT
Completed Phase 2 Interventional Results available

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT02807558
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Tamibarotene, Azacitidine, Daratumumab
Drug
Lead sponsor
Syros Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
14
States / cities
Hartford, Connecticut • Miami, Florida • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 5, 2026, 2:16 PM EDT
Completed No phase listed Observational

Erythropoietin Resistance in Anemia of Chronic Kidney Disease

NCT00526747
View directory record Official record
Conditions
Anemia, Kidney Failure, Erythropoietin
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Oct 5, 2026, 2:16 PM EDT